DNMT3A and myeloid neoplasm: Similarly, Dnmt3a ablation in HSCs predisposes mice to develop a spectrum of myeloid and lymphoid malignancies, and Dnmt3a-KO-derived myeloid malignancies and T cell acute lymphocytic leukemia/lymphoma show distinct methylation aberrations (Mayle et al. 2015).